Adenoviral Conjunctivitis

Okogen specializes in developing treatments which drastically accelerate viral clearance of adenoviral conjunctivitis and improve symptoms.

There are approximately 30 million cases of acute conjunctivitis annually worldwide

Viral conjunctivitis (a subtype of acute conjunctivitis), which may also be known as pink eye, is a serious ophthalmic infection with potential long-term negative effects.

Viral conjunctivitis results in moderate to severe inflammation of the conjunctiva, the mucous membrane that covers the front of the eye and lines the inside of the eyelids.

Corneal opacity occurs in 20-50% of viral conjunctivitis cases, and can lead to scarring or clouding of the cornea. Significantly, this may result in long-term visual impairment and premature/chronic dry eye.

Signs and symptoms of viral conjunctivitis include eye pain, redness, swelling and discharge, which cause significant discomfort and embarrassment.

Currently it takes 2-3 weeks to resolve without treatment. OKG-0502 will significantly shorten the infection and associated symptoms.

OKG-0502 Fixed Dose Combination


Alpha Adrenergic Receptor Agonist
(Sign & Symptom Relief)

Mechanism of Action(s)

Without Treatment

Virus causes conjunctivitis via replication in infected cells

With OKG-0301 Treatment

The anti-viral preferentially enters virally infected cells and inhibits viral replication

With OKG-0502 Treatment

The anti-viral inhibits viral replication and the ocular decongestant reduces redness & discharge